Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05084768 · ClinicalTrials.gov registry record
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
A clinical trial of Graft Failure and Acute Rejection of Renal Transplant, sponsored by Loma Linda University.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT05084768 is a study of Graft Failure and Acute Rejection of Renal Transplant that is actively recruiting participants, run by Loma Linda University. The registered enrollment target is 150 participants, above the 42-participant average among 5 other Graft Failure trials with a reported enrollment target (257% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05084768, a study of Graft Failure and Acute Rejection of Renal Transplant, is actively recruiting participants, sponsored by Loma Linda University.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Acute rejection after kidney transplantation should ideally be diagnosed prior to immunologic injury in a non-invasive fashion in order to improve long-term graft function. Donor-derived cell-free DNA (ddcfDNA) is a promising method to do so as it is elevated prior to acute rejection and has good predictive performance especially for antibody-mediated and high severity T-cell mediated rejection. Its ability to predict low severity T-cell mediated rejection and future graft function remains equivocal. Regulatory T cells (Tregs) are essential in transplant tolerance by suppressing effector immune responses. Circulating post-transplant highly suppressive HLA-DR+ Tregs were reduced in recipients who developed acute rejection. Preliminary results in a cohort including predominantly low severity T-cell mediated rejection also showed that pre-transplant circulating highly suppressive TNFR2+ Tregs were reduced in and could predict acute rejection. Integrating dd-cfDNA with HLA-DR+TNFR2+ Treg could improve the predictive performance for acute rejection especially of low severity and potentially predict graft function. Plasma dd-cfDNA and HLA-DR+TNFR2+ Tregs will be measured in 150 kidney transplant recipients at scheduled intervals during the first 6 months post-transplant. Predictive accuracy of a model integrating ddcfDNA and HLA-DR+TNFR2+ Treg for acute rejection will be tested using ROC curve analysis and multivariate logistic regression. Predictive accuracy for 1-year graft function will be tested using multivariate linear regression. High predictive performance for acute rejection and graft function using a model integrating dd-cfDNA and HLA-DR+TNFR2+ Treg would help identify kidney transplant recipients at immunologic risk early on and allow personalization of immunosuppression accordingly.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Donor-derived cell-free DNA
Study Locations (1)
California
- Loma Linda University Health - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2026-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05084768
The ClinicalTrials.gov registry entry for NCT05084768 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 42-participant average among 5 other Graft Failure trials with a reported enrollment target (257% higher). The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Graft Failure appearing as the primary indexed condition, and to 1 intervention - of which Donor-derived cell-free DNA is the first listed.
NCT05084768 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05084768 about?
NCT05084768 is a clinical study titled "Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection". Acute rejection after kidney transplantation should ideally be diagnosed prior to immunologic injury in a non-invasive fashion in order to improve long-term graft function. Donor-derived cell-free DNA (ddcfDNA) is a promising method to do so as it is elevated prior to acute rejection and has good pr...
What is the current status of trial NCT05084768?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2020-12-07. Estimated completion is 2026-10-01.
What conditions does trial NCT05084768 study?
This clinical trial studies the following conditions: Graft Failure, Acute Rejection of Renal Transplant.
What interventions are being tested in trial NCT05084768?
The interventions under investigation include: Donor-derived cell-free DNA (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05084768?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05084768 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
-
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
RECRUITING · Early Phase 1
-
CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
RECRUITING · NA
-
Tumescence in HNC Skin Graft Reconstruction
ACTIVE NOT RECRUITING · Phase 3
-
Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.